Opdivo + chemo approved as neoadjuvant treatment for NSCLC

Create PDF

This application was approved under the FDA’s real-time oncology review pilot program and was also conducted under the FDA’s Project Orbis initiative, which enabled concurrent review by the health authorities in Australia, Canada, and the United Kingdom, where the application remains under review.